Rayvow Euroopa Liit - eesti - EMA (European Medicines Agency)

rayvow

eli lilly nederland b.v. - lasmiditan succinate - migreenihäired - valuvaigistid - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

DAPTOMYCIN NORAMEDA süste-/infusioonilahuse pulber Eesti - eesti - Ravimiamet

daptomycin norameda süste-/infusioonilahuse pulber

norameda uab - daptomütsiin - süste-/infusioonilahuse pulber - 350mg 1tk; 350mg 5tk

DAPTOMYCIN NORAMEDA süste-/infusioonilahuse pulber Eesti - eesti - Ravimiamet

daptomycin norameda süste-/infusioonilahuse pulber

norameda uab - daptomütsiin - süste-/infusioonilahuse pulber - 500mg 1tk

TOBRAMYCIN VIA PHARMA nebuliseeritav lahus Eesti - eesti - Ravimiamet

tobramycin via pharma nebuliseeritav lahus

via pharma uab - tobramütsiin - nebuliseeritav lahus - 300mg 5ml 56tk

HAPNIK meditsiiniline surugaas Eesti - eesti - Ravimiamet

hapnik meditsiiniline surugaas

aktsiaselts elme messer gaas - hapnik - meditsiiniline surugaas - 100% 3l 1tk; 100% 50l 12tk; 100% 20l 1tk; 100% 40l 1tk; 100% 5l 1tk; 100% 150l 4tk; 100% 10l 1tk; 100% 2l 1tk; 100% 50l 1tk

Carvykti Euroopa Liit - eesti - EMA (European Medicines Agency)

carvykti

janssen-cilag international nv - ciltacabtagene autoleucel - mitu müeloomit - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Kimmtrak Euroopa Liit - eesti - EMA (European Medicines Agency)

kimmtrak

immunocore ireland limited - tebentafusp - uveal neoplasms - antineoplastilised ained - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Talvey Euroopa Liit - eesti - EMA (European Medicines Agency)

talvey

janssen-cilag international n.v. - talquetamab - mitu müeloomit - antineoplastilised ained - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Tepkinly Euroopa Liit - eesti - EMA (European Medicines Agency)

tepkinly

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastilised ained - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.